Livagen — Indexed Studies

Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial.

Xu H, Li F, Li B et al.

A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1.

Li T, Wu BL, Yu CL et al.

Unveiling lymphocyte dynamics: Navigating postoperative immune landscapes in gastric cancer patients undergoing laparoscopic D2 gastrectomy.

Gao C, Zhu L, Tong YX et al.

Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis.

Tian Y, Yao J, Ma Y et al.

Effect of thymosin α1 on Immune response and organ function in acute aortic dissection surgery: PANDA II trial protocol.

Liu H, Qian SC, Zhang YY et al.

Hypofractionated radiotherapy combined with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor, and thymosin-α1 in advanced metastatic solid tumors: a multicenter Phase II clinical trial.

Yu J, Yin L, Guo W et al.

Indications for an antidepressive effect of thymosin alpha-1 in a small open-label proof of concept study in common variable immune deficiency patients with depression.

Aynekulu Mersha DG, Fromme SE, van Boven F et al.

The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.

Wu J, Pei F, Zhou L et al.

PD-1 inhibitor combined with SBRT, GM-CSF, and thymosin alpha-1 in metastatic breast cancer: A case report and literature review.

Yu J, Wang Q, Wang L et al.

Effect of thymalfasin on myeloid-derived suppressor cells in patients with non-small cell lung cancer.

Shi F, Qiu H, Yan J et al.

Evaluation of the efficacy and safety of a precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumours: protocol for the open-label, prospective, multicentre study (PRaG5.0 study).

Kong Y, Chen R, Xu M et al.

Immune-Enhancing Treatment among Acute Necrotizing Pancreatitis Patients with Metabolic Abnormalities: A Post Hoc Analysis of a Randomized Clinical Trial.

Huang X, Mao W, Hu X et al.

The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression.

Soeroto AY, Suryadinata H, Yanto TA et al.

Thymosin α1 modulated the immune landscape of COVID-19 patients revealed by single-cell RNA and TCR sequencing.

Bai H, Liang L, Qi X et al.

Risk Factors and Drug Efficacy for Severe Illness in Hemodialysis Patients Infected with the Omicron Variant of COVID-19.

Wu Y, He L, Guo Y et al.

Palliative care and Chinese medicine in a centenarian with primary hepatocellular carcinoma and 27-month follow-up: A case report.

Hu Y, Lan XH, Cao YJ et al.

A Prospective and Randomized Control Study on Effects of Thymalfasin for Injection on Perioperative Immune Function and Long-term Prognosis of Patients with Colorectal Cancer.

Niu W, Li Z, Li Z et al.

Reduced numbers of naïve CD4 + T cells and an altered CD4/CD8 balance in depressed common variable immune deficiency (CVID) patients. Is thymosin-α1 a possible treatment?

Manusama O, Singh S, Brooimans RA et al.

Association between pretreatment lymphocyte count and efficacy of immune-enhancing therapy in acute necrotising pancreatitis: a post-hoc analysis of the multicentre, randomised, placebo-controlled TRACE trial.

Ke L, Mao W, Shao F et al.

A pilot trial of Thymalfasin (Ta1) to prevent covid-19 infection and morbidities in renal dialysis patients: Preliminary report.

Tuthill CW, Awad A, Parrigon M et al.

Thymosin alpha1 use in adult COVID-19 patients: A systematic review and meta-analysis on clinical outcomes.

Shang W, Zhang B, Ren Y et al.

A randomized controlled pilot trial of etanercept and alpha-1 antitrypsin to improve autologous islet engraftment.

Abdel-Karim TR, Hodges JS, Pruett TL et al.

A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection.

Shehadeh F, Benitez G, Mylona EK et al.

Value of Thymosin α1 Combined With Blood Purification to Increase Successful Rescues of Shock Patients.

Bai L, Qiu X, Ding X et al.

Efficacy of Thymosin α1 in Management of Radiation Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiotherapy: A Phase 2 Clinical Trial (GASTO-1043).

Liu F, Qiu B, Xi Y et al.

Clinical effect of Xuebijing combined with thymosinα1 on patients with severe pneumonia complicated with sepsis and its effect on serum inflammatory factors.

Chen Y, Zhou L, Wang J et al.

Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial.

Ke L, Zhou J, Mao W et al.

Safety and efficacy of Thymosin α1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial.

Chen JF, Chen SR, Lei ZY et al.

Hypofractionated Radiation Therapy Combined With Weekly Chemotherapy in Patients With Unresectable or Recurrent Thymic Epithelial Tumor: A Prospective, Single-Arm Phase 2 Study (GASTO-1042).

Chu C, Liang Y, Lin X et al.

Clinical efficacy of thymosin alpha 1 combined with multi-modality chemotherapy and its effects on immune function of patients with pulmonary tuberculosis complicated with diabetes.

Wu L, Luo PP, Tian YH et al.

Impact of thymosin α1 as an immunomodulatory therapy on long-term survival of non-small cell lung cancer patients after R0 resection: a propensity score-matched analysis.

Guo CL, Mei JD, Jia YL et al.

Epigenetic Therapy Promotes the Ratio of Th1/Th17 Lineage to Reverse Immune Evasion and Treat Leukemia Relapse Post-allogeneic Stem Cell Transplantation in Non-APL AML Patients.

Xi Y, Jingying D, Chenglong L et al.

Postpartum extracorporeal membrane oxygenation of a woman with COVID-19-related acute respiratory distress syndrome: A case report.

Huang W, Cheng Z, Liao X et al.

Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients.

Wang Z, Chen J, Zhu C et al.

Efficacy Evaluation of Thymosin Alpha 1 in Non-severe Patients With COVID-19: A Retrospective Cohort Study Based on Propensity Score Matching.

Huang C, Fei L, Xu W et al.

The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients.

Bersanelli M, Giannarelli D, Leonetti A et al.

Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients.

Matteucci C, Minutolo A, Balestrieri E et al.

Delayed discharge is associated with higher complement C3 levels and a longer nucleic acid-negative conversion time in patients with COVID-19.

Lin P, Chen W, Huang H et al.

The effect of thymosin α1 on mortality of critical COVID-19 patients: A multicenter retrospective study.

Sun Q, Xie J, Zheng R et al.

Thymosin alpha 1 in the prevention of infected pancreatic necrosis following acute necrotising pancreatitis (TRACE trial): protocol of a multicentre, randomised, double-blind, placebo-controlled, parallel-group trial.

Zhou J, Mao W, Ke L et al.

Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study.

Wu M, Ji JJ, Zhong L et al.

Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report.

Liang B, Chen J, Li T et al.

CD3(+), CD4(+), and CD8(+) Expression in Cells in Peripheral Blood of Silicosis Patients and Intervention Effect of Thymalfasin.

Xiong W, Liu ZG, Xiong L et al.

Severe Gastric Mycormycosis Infection Followed by Cytomegalovirus Pneumonia in a Renal Transplant Recipient: A Case Report and Concise Review of the Literature.

Peng H, Xiao J, Wan H et al.

The effect of thymopentin add-on in hepatitis B e antigen positive chronic hepatitis B after virus suppression by peginterferon plus entecavir therapy.

Ma Y, Bao X, Xiong F et al.

Chronic active EBV infection associated with NK cell lymphoma and hemophagocytic lymphohistiocytosis in a 27-year-old woman: A case report.

Wang YD, Wu LL, Ma LY et al.

Stereotactic body radiation therapy and thymosin alpha-1-induced anti-tumor effects in heavily pretreated, metastatic esophageal squamous cell carcinoma patients.

Du D, Song T, Dai H et al.

Thymosin alpha 1 treatment for patients with sepsis.

Pei F, Guan X, Wu J

Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study.

Wu X, Shi Y, Zhou J et al.

The effect of thymosin α1 for prevention of infection in patients with severe acute pancreatitis.

Yang N, Ke L, Tong Z et al.

Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy.

Danielli R, Cisternino F, Giannarelli D et al.

[Clinical research on sequential dual-drug nonspecific immunotherapy in patients with hepatocellular carcinoma].

Zhou JP, Yao SY, Chen YY et al.

[Effect of transcatheter arterial chemoembolization combined with thymosin alpha 1 on the autophagy of immune cells from advanced hepatocellular carcinoma].

Fang SJ, Zheng LY, Zhao ZW et al.

Thymosin-α1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients.

Giacomini E, Rizzo F, Etna MP et al.

Effect of ulinastatin combined with thymosin alpha1 on sepsis: A systematic review and meta-analysis of Chinese and Indian patients.

Liu D, Yu Z, Yin J et al.

Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases.

Pica F, Chimenti MS, Gaziano R et al.

Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection.

Al-Mahtab M, Bazinet M, Vaillant A

[Prevention Effect of Thymosin-alpha1 Aganist Early Ventilator-associated Pneumonia in Patients with Mechanical Ventilation].

Zhang SS, Li K, Wang YH et al.

[Effect of Acupuncture on Prognosis and Immune Function of Sepsis Patients].

Xiao QS, Ma MY, Zhang XS et al.

Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients.

Jia Z, Feng Z, Tian R et al.

A multicenter, randomized, observation-controlled clinical trial to evaluate the efficacy and safety of thymalfasin adjuvant therapy in patients with HBV-related HCC after curative resection - first announcement of the protocol.

Qiu SJ, Zhou ZG, Shen F et al.